QT
ESPR

Quantamental Technologies’s Esperion Therapeutics ESPR Stock Holding History

Quantamental Technologies’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-5,376
Closed -$250K – 1605
2019
Q2 		$250K Buy
+5,376
New +$252K 0.09% 368

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Quantamental Technologies's ESPR Position: Q3 2019 in Review

Quantamental Technologies sold out of Esperion Therapeutics (ESPR) in Q3 2019, closing a stake of 5,376 shares — an estimated $250K sold.

Quantamental Technologies first reported a position in ESPR in Q2 2019 and held it in 1 quarter. The position peaked at $250K in Q2 2019. 152 funds tracked by Wall St. Rank hold ESPR as of Q3 2019.

  • Quantamental Technologies reported no remaining Esperion Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Quantamental Technologies sold 5,376 Esperion Therapeutics shares in Q3 2019, an estimated $250K.
  • Quantamental Technologies first reported a position in Esperion Therapeutics in Q2 2019 and held it in 1 quarter.
  • Quantamental Technologies's Esperion Therapeutics position peaked at $250K in Q2 2019.
  • 152 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2019.

Based on Quantamental Technologies's 13F filing for Q3 2019, filed 8 Nov 2019.